Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.47 |
| ▸ | PDE4A | P27815 | 8/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2282287 | 0.98 | CSNK2A1 (0.49) | CSNK2A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15711376 | 0.91 | CSNK2A1 (0.61) | CSNK2A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15711391 | 0.88 | CSNK2A1 (0.43) | CSNK2A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8258256 | 0.85 | CSNK2A1 (0.41) | CSNK2A1LOXL2 | |
| SCHEMBL2440368 | 0.85 | CSNK2A1 (0.45) | CSNK2A1PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL25370524 | 0.83 | CSNK2A1 (0.42) | CSNK2A1LOXL2 | |
| SCHEMBL19664448 | 0.83 | CSNK2A1 (0.47) | CSNK2A1 | |
| Hydrochloric Acid SCHEMBL30580207 | 0.83 | CSNK2A1 (0.42) | CSNK2A1LOXL2 | |
| SCHEMBL13343804 | 0.83 | CYP1A2 (0.45) | CSNK2A1PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL3566436 | 0.82 | LMNA (0.46) | CSNK2A1ST14KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323985-B1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2017-01-11 | — | — | EP | disclosed |
| EP-2349262-B1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8399494-B2 | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399494-B2 | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8349872-B2 | Tripyridyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349872-B2 | Tripyridyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20110301140-A1 | Pyridine Carboxamide orexin Receptor Antagonists | BERGMAN JEFFREY M (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301140-A1 | Pyridine Carboxamide orexin Receptor Antagonists | BERGMAN JEFFREY M (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110207747-A1 | 2,5-Disubstituted Phenyl Carboxamide Orexin Receptor Antagonists | MERCK & CO., INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207747-A1 | 2,5-Disubstituted Phenyl Carboxamide Orexin Receptor Antagonists | MERCK & CO., INC. | 2011-08-25 | — | — | US | disclosed |
| US-20100197652-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. | 2010-08-05 | — | — | US | disclosed |
| WO-2010051237-A1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010017260-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-02-11 | — | — | US | disclosed |
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-02-11 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2009020642-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | CSNK2A1 4586/4885PDE4A 1664/4885PDE4B 2114/4885 |
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NTSR2 | CSNK2A1 2925/4885PDE4A 2140/4885PDE4B 2157/4885 |
| US-20110207747-A1 | 2,5-Disubstituted Phenyl Carboxamide Orexin Receptor Antagonists | HCRTR2, HCRTR1, CRHR2 | CSNK2A1 3143/4885PDE4A 2036/4885PDE4B 1488/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | CSNK2A1 4586/4885PDE4A 1664/4885PDE4B 2114/4885 |
| US-20100197652-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | CSNK2A1 2366/4885PDE4A 1323/4885PDE4B 1413/4885 |
| US-20110301140-A1 | Pyridine Carboxamide orexin Receptor Antagonists | HCRTR2, HCRTR1, NPY1R | CSNK2A1 2366/4885PDE4A 1323/4885PDE4B 1413/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | CSNK2A1 4586/4885PDE4A 1664/4885PDE4B 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.